Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491454 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL29401132 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL29400299 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL119702 | 1.00 | MDM4 (0.55) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL4404683 | 0.91 | PTPN1 (0.49) | MDM4TP53SLC17A5 | |
| SCHEMBL12088806 | 0.90 | MDM4 (0.48) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL3492803 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL10020438 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL1739174 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL22636161 | 0.89 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020238800-A1 | TARGETED RADIOPHARMACEUTICALS FOR TUMORS, AND COMBINATION THERAPY OF TARGETED RADIOTHERAPY THEREOF AND IMMUNOTHERAPY UNDER GUIDANCE OF IMAGES | 北京大学 | 2020-12-03 | — | — | WO | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | MDM4 3636/4885TP53 342/4885SLC17A5 2570/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | MDM4 3432/4885TP53 1898/4885SLC17A5 2649/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | MDM4 3611/4885TP53 2646/4885SLC17A5 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.